www.fiercebiotech.com Open in urlscan Pro
104.18.1.165  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Webinar


UNLEASHING INNOVATION: A NEW OBESOGENIC NASH MODEL WITH HIGH CLINICALLY
TRANSLATIONAL POWER

Apr 22, 2024 10:00am ET
60 Minutes
Share
share on linkedin
share on X
share on facebook
share on email
copy link

Are you curious about cutting-edge advancements in NASH disease research?

Join us for an exciting look at the innovative new drug R&D strategies behind a
novel NAFLD/NASH animal model. See how this recent development delivers key
insights into liver diseases as it mirrors real patient experiences. We’ll take
a deep dive into in vitro phenotypic models, the utilization of human cells, and
the effects of Resmetirom on inhibiting fat accumulation.

What to Expect:

 * See firsthand how this model aligns with clinical trial studies for confident
   results
 * Learn how to gain key NASH indicators in just 12-16 weeks
 * Discover the significant cost and time savings in comparison to traditional
   methods
 * And much more

Don’t miss out, register today. Let's shape the future of NASH research
together!


SPEAKERS


JOHN LIU

Head of Pharmacology, Discovery
BioDuro-Sundia

Yongqiang Liu (John), with 18 years in drug discovery and CRO operations, leads
the pharmacology department at BioDuro-Sundia since 2019. His focus spans
immunology, inflammation, neurodegeneration, cardiovascular, and metabolic
diseases. Formerly at CrownBio for 8 years, he excelled in cardiovascular and
metabolic diseases, contributing to oncology studies. Noteworthy achievements
include leading R&D projects and external studies. In 2008-2011, John Liu worked
on GPCR-related drug research at Argusina, and earlier, he successfully managed
a clinical trial-approved drug project at Wolwo Biotech. With expertise in NASH,
he dedicates over a decade to NASH animal model development, accumulating 10+
years of experience. Author of 8 peer-reviewed publications.


LIN TENG

Vice President of Integrated Biology, Discovery
BioDuro-Sundia

With 15 years of drug development research experience in top pharmaceutical
companies and CROs, Lin Teng excels in target identification/validation, assay
development, pre-clinical studies, translational research, and mechanism
exploration. Lin Teng gained her Ph.D. from the Shanghai Institute of
Biochemistry and Cell Biology, Chinese Academy of Sciences, and joined
BioDuro-Sundia in 2020. As the head of Integrated Biology, she leads global
collaborations, overseeing the development of comprehensive assays and screening
compounds for all major drug target classes. Lin Teng previously contributed to
Novartis and Johnson & Johnson, focusing on epigenetic drugs for oncology and
hematological malignancies. With 9 peer-reviewed publications, Lin Teng
continues to drive impactful advancements in drug development.


REGISTER HERE!

Already registered? Click here to login.
Date/Time:
Apr 22, 2024 10:00am ET
Duration:
60 Minutes

 * Connect
   
   * The Team
   * Advertise
 * Join Us
   
   * Newsletters
   * Resources
   * RSS Feeds
 * Our Brands
   
   * Fierce Pharma
   * Fierce Biotech
   * Fierce Healthcare
 * Our Events
   
   * Life Sciences Events

©2024 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings